Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.71 |
| ▸ | CCND1 | P24385 | 17/20 | 0.71 |
| ▸ | CCND3 | P30281 | 9/20 | 0.71 |
| ▸ | CDK2 | P24941 | 7/20 | 0.71 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.71 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.71 |
| ▸ | FECH | P22830 | 1/20 | 0.71 |
| ▸ | CDK9 | P50750 | 1/20 | 0.71 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.71 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.71 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.71 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.71 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.71 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.71 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | CCND2 | P30279 | 8/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005415 | 0.91 | CDK4 (0.73) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228935 | 0.90 | CDK4 (0.61) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228964 | 0.88 | CDK4 (0.59) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228948 | 0.87 | CDK1 (0.66) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL23767830 | 0.87 | CDK1 (0.64) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228956 | 0.87 | CDK1 (0.66) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228960 | 0.87 | CDK4 (0.65) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228963 | 0.86 | CDK4 (0.67) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL20228942 | 0.84 | CDK4 (0.68) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL24267474 | 0.83 | CDK2 (0.55) | CDK4CCND1CCND3CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022177843-A1 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND ABEMACICLIB OR RIBOCICLIB | GENENTECH, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220079944-A1 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | BETA PHARMA, INC. | 2022-03-17 | — | — | US | disclosed |
| US-10752687-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2020-08-25 | — | — | US | disclosed |
| US-10472419-B2 | Antibody molecules to TIM-3 and uses thereof | NOVARTIS AG (CH) | 2019-11-12 | — | — | US | disclosed |
| US-20180155427-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | BIOATLA, LLC | 2018-06-07 | — | — | US | disclosed |
| US-20170306038-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170198041-A1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079944-A1 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | CDK6, CDK4, CDK3 | CDK4 2/4885CCND1 50/4885CCND3 46/4885 |
| US-20170306038-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | CD4, IL2RA, IL2 | CDK4 1698/4885CCND1 3078/4885CCND3 2696/4885 |
| US-10752687-B2 | Antibody molecules to PD-1 and uses thereof | CD274, PDCD1, PDCD1LG2 | CDK4 1346/4885CCND1 2839/4885CCND3 3938/4885 |
| US-20170198041-A1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | HAVCR2, TIMM13, LGALS3BP | CDK4 3399/4885CCND1 4782/4885CCND3 4021/4885 |
| US-10472419-B2 | Antibody molecules to TIM-3 and uses thereof | HAVCR2, TIMM13, LGALS3BP | CDK4 3399/4885CCND1 4782/4885CCND3 4021/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CDK4 7/4885CCND1 20/4885CCND3 40/4885 |
| US-20180155427-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | CD274, PDCD1, PDCD1LG2 | CDK4 1346/4885CCND1 2839/4885CCND3 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.